{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T05:17:46Z","timestamp":1739942266226,"version":"3.37.3"},"reference-count":13,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1124\/dmd.107.014696","type":"journal-article","created":{"date-parts":[[2007,4,13]],"date-time":"2007-04-13T00:39:32Z","timestamp":1176424772000},"page":"1196-1202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Absorption, Metabolism, and Excretion of [14C]MK-0524, a Prostaglandin D2 Receptor Antagonist, in Humans"],"prefix":"10.1016","volume":"35","author":[{"given":"Bindhu","family":"Karanam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Madeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa","family":"Wenning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Soli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Dean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Doss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graigory","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tami","family":"Crumley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Nirula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.107.014696_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0009-2797(03)00020-6","article-title":"Acyl glucuronide reactivity in perspective: biological consequences","volume":"145","author":"Bailey","year":"2003","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.107.014696_bib2","doi-asserted-by":"crossref","DOI":"10.1080\/00498250601175565","article-title":"The pharmacokinetics and disposition of MK-0524 a prostaglandin D2 receptor 1 antagonist, in rats, dogs and monkeys","author":"Chang","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.107.014696_bib3","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad SciUSA"},{"key":"10.1124\/dmd.107.014696_bib4","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.106.011551","article-title":"Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans","volume":"35","author":"Dean","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.014696_bib5","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1016\/0006-2952(85)90728-2","article-title":"Distribution of glucuronidation capacity (1-naphthol and morphine) along the rat intestine","volume":"34","author":"Koster","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.107.014696_bib6","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJM199908123410707","article-title":"Drug treatment of lipid disorders","volume":"341","author":"Knopp","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.107.014696_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bmcl.2006.10.055","article-title":"In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites","volume":"17","author":"Nicoll-Griffith","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/dmd.107.014696_bib8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.amjcard.2004.04.024","article-title":"Safety and compliance with once-daily niacin extended-release\/lovastatin as initial therapy in the Impact of Medical Subspeciality on Patient Compliance to Treatment (IMPACT) Study","volume":"94","author":"Rubenfire","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1124\/dmd.107.014696_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jchromb.2006.04.022","volume":"837","author":"Schwartz","year":"2006","journal-title":"J Chromatogr B"},{"key":"10.1124\/dmd.107.014696_bib10","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1172\/JCI109385","article-title":"Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoptotein A metabolism","volume":"63","author":"Shepherd","year":"1979","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.107.014696_bib11","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1021\/jm0603668","article-title":"Discovery of a potent and selective PGD2 receptor antagonist [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopentaindol-3-yl]-acetic acid (MK-0524)","volume":"50","author":"Sturino","year":"2007","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.107.014696_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1185\/030079906X89766","article-title":"Evaluations of safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS Study","volume":"22","author":"Vogt","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/dmd.107.014696_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.amjcard.2003.10.009","article-title":"Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study)","volume":"93","author":"Zhao","year":"2004","journal-title":"Am J Cardiol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624013564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624013564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.107.014696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:22:58Z","timestamp":1739895778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624013564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0090955624013564"],"URL":"https:\/\/doi.org\/10.1124\/dmd.107.014696","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2007,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Absorption, Metabolism, and Excretion of [14C]MK-0524, a Prostaglandin D2 Receptor Antagonist, in Humans","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.107.014696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}